Gongwin Biopharm Holdings

Gongwin Biopharm Holdings is a biotechnology company focused on developing Point Target Therapy for cancer treatment using its proprietary Para-Toluenesulfonamide (PTS) platform. The company's lead product, PTS302, is a chemical ablation agent that has received marketing approval in China for treating central-type non-small cell lung cancer. Gongwin's technology involves the direct injection of PTS into tumor tissue, where it selectively induces necrosis in cancer cells while sparing healthy tissue. Beyond lung cancer, the company is expanding its pipeline to include treatments for liver cancer, malignant pleural effusion, and head and neck cancers. Additionally, Gongwin has established a veterinary division to apply its PTS technology to treat solid tumors in companion animals.